Durham's Incyclix Bio raises $52M for gentler cancer therapies
What's the deal? Durham-based Incyclix Bio has raised $52 million in a late-stage venture round to advance precision treatments for breast and ovarian cancers now in clinical trials. Investors include Eshelman VenturesDealroom has a profile for this one. Try Dealroom →, Cape Fear BioCapitalDealroom has a profile for this one. Try Dealroom →, NC BiotechDealroom has a profile for this one. Try Dealroom →, and Hatteras Venture Partners.
What's the endgame? The biotech, founded in 2020 by Patrick Roberts, Jay Strum, and John Bisi, is developing CDK2 inhibitors that aim to curb tumor growth with fewer side effects than traditional chemotherapy. Its lead drug, INX 315, adds a CDK2 inhibitor on top of existing treatments to overcome resistance that lets cancer return.
How it works: Cancer grows when proteins called cyclins keep signaling cells to divide. CDK inhibitors block that signal, but Roberts says resistance builds over time. "CDK2 can come in and override that and keep pushing the cell cycle forward," he said.
Why now? INX 315 is in trials across 19 hospitals, targeting patients whose breast or ovarian cancer progressed despite earlier CDK4/6 treatment. The approach aligns with an FDA initiative, Project Optimus, that urges developers to find the lowest effective dose rather than pushing to the maximum.
Roberts, who spent part of his PhD in an oncology ward, said the goal is reducing harm. "You're not getting any additional benefit. You're just creating more adverse events," he said of high-dose chemotherapy.
Incyclix spun out of G1 Therapeutics, the Research Triangle biopharma acquired by Denmark's PharmacosmosDealroom has a profile for this one. Try Dealroom → for $405 million in 2024. Its three cofounders — also G1's first three employees — bought the IP for CDK2 inhibitors to pursue the treatment-resistance problem.
What's next? The company expects to present early findings from 60 patients at the San Antonio Breast Cancer Symposium in December, aiming to kickstart a fresh raise in early 2027. Roberts intends to keep operations in North Carolina despite investor interest in relocating.
The signal: At $52 million, the round sits in the top quartile of comparable deals, a notable vote of confidence in the Research Triangle's biotech cluster. It signals continued investor appetite for precision oncology that prioritizes quality of life alongside efficacy.
Read more: technical.ly
Image credit: Incyclix Bio
